Despite $2B Deal, J&J's Risperdal Fight Rages On In Pa.
Johnson & Johnson's blockbuster $2.2 billion Risperdal settlement resolves off-label marketing claims over the anti-psychotic drug, but it will have little effect on product liability litigation in Pennsylvania, where plaintiffs attorneys...To view the full article, register now.
Already a subscriber? Click here to view full article